The VITamin D and OmegA-3 TriaL (VITAL) is an ongoing randomized clinical trial of 25,871
U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000
IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer,
heart disease, and stroke in individuals who do not have a prior history of these illnesses.
The purpose of this ancillary study is to ascertain and adjudicate atrial fibrillation (AF)
outcomes for the primary aim of testing whether omega-3 fatty acid and/or vitamin D
supplementation influence atrial fibrillation risk in the general population. We also plan to
examine how these agents might impact the development of AF subtypes (persistent versus
paroxysmal), intermediate phenotypes for heart rhythm disorders (electrocardiographic
parameters), as well as explore effects on arrhythmic death and whether baseline blood levels
and/or race modify treatment effects.
Phase:
Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins